ホーム>>Signaling Pathways>> GPCR/G protein>> Prostaglandin Receptor>>Licarin A

Licarin A

カタログ番号GC60225

ネオリグナンであるリカリン A ((+)-リカリン A) は、ジニトロフェニル-ヒト血清アルブミン (DNP-HSA) 刺激 RBL-2H3 細胞における TNF-α 産生 (IC50=12.6 μM) を用量依存的に有意に減少させる.

Products are for research use only. Not for human use. We do not sell to patients.

Licarin A 化学構造

Cas No.: 51020-86-1

サイズ 価格 在庫数 個数
1mg
$121.00
在庫あり
5mg
$297.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Licarin A ((+)-Licarin A), a neolignan isolated from various plants, significantly and dose-dependently reduces TNF-α production (IC50=12.6±0.3 μM) in dinitrophenyl-human serum albumin (DNP-HSA)-stimulated RBL-2H3 cells. Anti-allergic effects. Licarin A reduces TNF-α and PGD2 production, and COX-2 expression[1].

Licarin A is found in plants such as Aristolochia taliscana, Machilus thunbergii and Myristica fragrans, which are used as spices and in folk medicines for nervous and digestive disorders. Licarin A also exhibits anti-inflammatory effects[1]. Licarin A (5-20 μM) reduces TNF-α and prostaglandin D2 (PGD2) secretion via the inhibition of PKCα/βII and p38 MAPK pathways. Licarin A treatment tends to reduce phosphorylated PKCα/βII and p38 MAPK protein levels[1].

[1]. Takuya Matsui, et al. Licarin A Is a Candidate Compound for the Treatment of Immediate Hypersensitivity via Inhibition of Rat Mast Cell Line RBL-2H3 Cells. J Pharm Pharmacol. 2015 Dec;67(12):1723-32.

レビュー

Review for Licarin A

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Licarin A

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.